Does Testosterone Therapy Cause Prostate Cancer?

Physician-reviewed TRT safety education

Does Testosterone Therapy Cause Prostate Cancer?

Current evidence has not demonstrated that appropriately prescribed testosterone replacement therapy causes prostate cancer. That does not mean prostate health can be ignored: baseline assessment, PSA interpretation and individualized follow-up remain important.

Medically reviewed by Dr. Timothy Mackey
Medical Director · Updated September 2026

Why was testosterone historically linked to prostate cancer?

Prostate tissue is androgen responsive, and androgen-deprivation therapy can slow many prostate cancers. Those facts historically led to the assumption that giving testosterone would necessarily initiate or accelerate prostate cancer.

Modern evidence has shown the relationship is more complex. The fact that lowering androgens can treat established prostate cancer does not prove that physiologic testosterone replacement creates a new cancer in a man who does not have one.

What do major guidelines say?

The AUA testosterone-deficiency guideline states that clinicians should inform patients that there is an absence of evidence linking testosterone therapy to the development of prostate cancer. At the same time, men with a history of prostate cancer should be told that evidence is inadequate to precisely quantify the risk-benefit ratio of testosterone therapy.

The Endocrine Society also recommends prostate-risk assessment in appropriate men before treatment and follow-up after therapy begins.

What does the clinical evidence show?

Randomized trials and observational studies have not demonstrated a clear increase in incident prostate cancer among appropriately selected men receiving testosterone, although prostate cancer was not the primary endpoint of many older trials and long-term certainty has limits.

A large randomized prostate-safety analysis from the TRAVERSE program followed men with hypogonadism who were screened to exclude those at high prostate-cancer risk. Rates of high-grade or any prostate cancer were low and did not differ significantly between testosterone and placebo groups during the trial's follow-up. Because few cancers occurred, this does not establish equal risk between groups or exclude a longer-term risk.

This is reassuring evidence for men resembling the studied population; it should not be extrapolated to men with unevaluated abnormal PSA findings or active prostate cancer.

What is PSA and why does it matter before TRT?

Prostate-specific antigen (PSA) is produced by prostate tissue. PSA can be elevated because of prostate cancer, benign prostate enlargement, inflammation, infection and other factors. It is therefore a risk marker—not a cancer diagnosis.

The AUA testosterone-deficiency guideline recommends baseline PSA testing in men over 40 before TRT. A baseline result can identify findings requiring evaluation and provide a reference for comparison; PSA alone does not exclude cancer.

Does TRT increase PSA?

PSA may rise modestly after testosterone treatment, particularly in men starting with lower testosterone. A rise does not automatically mean cancer, but the magnitude, timing, baseline value, age and individual risk factors determine whether further evaluation is needed.

Unexpected PSA changes should be evaluated rather than dismissed as “just the testosterone.”

Who should have prostate evaluation before starting TRT?

Prostate assessment depends on age, symptoms, baseline risk and shared decision-making. The Endocrine Society recommends against starting testosterone in men with prostate cancer or concerning prostate findings that have not been appropriately evaluated, including certain elevated PSA values.

Men with a strong family history or other factors associated with higher prostate-cancer risk may warrant earlier or more individualized assessment.

What if the PSA is elevated before TRT?

An elevated PSA should not automatically be labeled prostate cancer, but it should be interpreted before treatment is started. Depending on the result and clinical context, repeat PSA testing, examination, urology referral, prostate MRI or other evaluation may be appropriate.

The key principle is to investigate a concerning baseline finding rather than start TRT first and sort it out later.

What if PSA rises after starting testosterone?

PSA changes should be interpreted using the patient's baseline, age, prostate history and treatment duration. During the first 12 months, the Endocrine Society recommends urologic consultation for a confirmed PSA increase greater than 1.4 ng/mL above baseline, a confirmed PSA above 4 ng/mL, or an abnormal prostate examination. Results should be confirmed and interpreted clinically; these are referral criteria, not a diagnosis of cancer.

TRT should be monitored as part of comprehensive medical care, not only by checking the testosterone level.

Can a man with previous prostate cancer ever use TRT?

This is a specialist-level, individualized decision. Some observational evidence suggests testosterone may be considered in carefully selected men after definitive treatment for localized prostate cancer, but the evidence is not strong enough to make a universal recommendation.

The AUA explicitly notes that evidence is inadequate to quantify the risk-benefit ratio in men with a history of prostate cancer. Decisions should involve the patient's urologist or oncology team when appropriate, cancer stage and grade, treatment status, recurrence risk, PSA trajectory, symptoms and goals.

What about men with active prostate cancer?

Testosterone replacement should not be approached as routine care in men with active or unevaluated prostate cancer. Androgen signaling remains clinically important in prostate-cancer biology, and androgen-deprivation therapy is a cornerstone of treatment for many advanced cancers.

Anyone with active disease should make hormone decisions with the clinicians managing the cancer.

Does TRT cause benign prostate enlargement?

The prostate is androgen responsive, but urinary symptoms and benign prostatic hyperplasia (BPH) are multifactorial. Clinical trial data have not shown that appropriately prescribed TRT universally causes clinically significant worsening of lower urinary tract symptoms.

New urinary symptoms—difficulty urinating, weak stream, retention, blood in the urine or other concerning changes—still deserve medical evaluation.

What symptoms can prostate cancer cause?

Early prostate cancer often causes no symptoms, which is why symptom absence cannot rule it out. More advanced disease may produce urinary symptoms, blood in urine or semen, bone pain, weight loss or other findings, but these symptoms can also arise from noncancerous conditions.

Screening and diagnostic evaluation are different processes. PSA alone neither proves nor excludes cancer.

TRT and prostate cancer: practical decision framework

• Confirm that testosterone deficiency is actually present before considering TRT.
• Assess prostate risk based on age, history and individual risk factors.
• Evaluate concerning PSA or examination findings before starting treatment.
• Establish an appropriate baseline when PSA monitoring is indicated.
• Monitor after treatment according to age, risk, guideline principles and shared decision-making.
• Refer to urology when PSA changes or prostate findings warrant specialist assessment.

For baseline testing, see our blood tests before TRT guide. For the broader treatment process, see our testosterone replacement therapy guide.

What about other cancers or a different cancer history?

Prostate studies cannot establish safety for breast, testicular or blood cancers. The Endocrine Society advises against starting testosterone in men with breast cancer. A new breast or testicular lump needs evaluation; testicular shrinkage during TRT is a different issue. Men with any cancer history should discuss hormone treatment with their treating specialists rather than generalize from prostate-trial results. See our broader TRT and cancer-risk overview for cancer-type distinctions and individual-history considerations.

Frequently asked questions

Does TRT feed prostate cancer?

Established prostate cancer can be androgen responsive, which is why androgen deprivation is used therapeutically. That is different from saying physiologic TRT has been shown to cause a new prostate cancer. Men with active or previous cancer require individualized specialist evaluation.

Can TRT cause my PSA to rise?

Yes, PSA can increase modestly in some men after testosterone treatment. A rise should be interpreted clinically and may require repeat testing or urologic evaluation depending on its magnitude and context.

Does a high PSA mean I have prostate cancer?

No. PSA can rise for multiple reasons. It is a marker used in risk assessment and monitoring, not a stand-alone cancer diagnosis.

Should I get a PSA before TRT?

The AUA recommends a baseline PSA in men over 40 before TRT. Discuss your individual risk and monitoring plan with the clinician.

Can TRT prevent prostate cancer?

No. Current evidence should not be interpreted to mean testosterone prevents prostate cancer. The appropriate conclusion is that available evidence has not demonstrated that properly prescribed TRT causes prostate cancer.

Medical references

• American Urological Association: Testosterone Deficiency Guideline
• Endocrine Society: Testosterone Therapy in Men With Hypogonadism
• JAMA Network Open: Prostate Safety Events During Testosterone Replacement Therapy
• National Cancer Institute: Prostate-Specific Antigen Test

This article is educational and does not replace individualized medical advice, cancer screening, diagnosis or treatment. Men with known or suspected prostate cancer should make testosterone decisions with the clinicians managing their prostate disease.